Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents.
Ananthula HK, Parker S, Touchette E, Buller RM, Patel G, Kalman D, Salzer JS, Gallardo-Romero N, Olson V, Damon IK, Moir-Savitz T, Sallans L, Werner MH, Sherwin CM, Desai PB.
Ananthula HK, et al. Among authors: parker s.
BMC Pharmacol Toxicol. 2018 Dec 4;19(1):80. doi: 10.1186/s40360-018-0270-x.
BMC Pharmacol Toxicol. 2018.
PMID: 30514402
Free PMC article.